We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Stanbio Acquires GDS Technology

By HospiMedica staff writers
Posted on 19 Sep 2001
Stanbio Laboratory (Boerne, TX, USA) has acquired GDS Technology (Elkhart, IN, USA), a manufacturer of clinical chemistry reagents, enzymes, and the Stat-Site multi-analyte point-of-care analyzer.

Stanbio manufactures clinical diagnostic reagents and products for serology, microbiology, and hematology. More...
The company's international distribution network is established in more than 70 countries around the world. The acquisition will further expand Stanbio's original equipment manufacturer (OEM) capabilities. Stanbio will also benefit from the research partnerships GDS has formed to explore its proprietary enzyme technology, which include the U.S. National Institutes of Health and the U.S. Department of Defense.

"With the addition of GDS Technology, we can strengthen our clinical chemistry line, which remains our core business, and further expand our product offering to include point-of-care testing,” said William R. Pippin, present of Stanbio Laboratory. "In addition, the unique synergy between our two operations will create numerous business opportunities as we merge the businesses.”




Related Links:
Stanbio
GDS Technology

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Automatic CLIA Analyzer
Shine i6000
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.